Safety of Covid-19 vaccination in patients with mastocytosis
Allergy: European Journal of Allergy and Clinical Immunology
; 78(Supplement 111):663, 2023.
Article
in English
| EMBASE | ID: covidwho-2301693
ABSTRACT
Background:
Mastocytosis is a disorder characterized by an accumulation of mast cells in one or more organ systems and increased risk for severe anaphylaxis. Coronavirus disease 2019 (COVID-19) is associated with a relatively high rate of severe lung disease and mortality. During 2020, vaccines against COVID-19 were developed. The reported frequency of severe side effects appears to be low even in patients with severe allergies and mastocytosis. The aim of this study was to evaluate the safety of vaccines against COVID-19 in patients with mastocytosis. Method(s) Retrospective analysis of patients with a diagnosis of mastocytosis who have been vaccinated against COVID-19 in our department, from January to December 2021. Demographic data, history of anaphylactic reactions, COVID-19 vaccines used, premedication with antihistamines and hypersensitivity reactions were reviewed. Result(s) This study included 14 patients (64% (n = 9) were female, median age 51 +/- 18 years). Twelve (86%) patients had indolent systemic mastocytosis and two (14%) had cutaneous mastocytosis. Four (29%) patients had a history of idiopathic anaphylaxis, three (21%) reported anaphylaxis to hymenoptera venoms and one (7%) anaphylaxis to NSAID. The median basal serum tryptase level was 38.9 ng/ml, with a range from 12.7 to 91 ng/ml. Thirteen (93%) patients received an mRNA vaccine, and one adenoviral vector vaccine (7%), 2 doses each (28 administrations in total). None of the patients received premedication with antihistamines before the vaccination. None of the patients presented hypersensitivity reactions after the vaccine against COVID-19. Conclusion(s) As reported in recent studies, vaccination against COVID-19 in adult patients with mastocytosis is safe. Some authors recommend premedication in patients with mastocytosis at high risk for anaphylaxis. In our study, none of the patients received premedication and no hypersensitivity reactions were observed. More studies are needed, but in our sample, as observed for other vaccines, the vaccine against COVID-19 in patients with mastocytosis was safe.
adult; allergy; anaphylaxis; clinical article; conference abstract; controlled study; coronavirus disease 2019; demographics; drug safety; drug therapy; female; gene expression; human; human cell; hypersensitivity; indolent systemic mastocytosis; mastocytosis; middle aged; retrospective study; side effect; urticaria pigmentosa; vaccination; adenovirus vector; antihistaminic agent; endogenous compound; Hymenoptera venom; nonsteroid antiinflammatory agent; plasmin; RNA vaccine; SARS-CoV-2 vaccine
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Topics:
Vaccines
Language:
English
Journal:
Allergy: European Journal of Allergy and Clinical Immunology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS